Anemia Treatment Guidelines

Diagnostic Approach

The American College of Physicians defines anemia as a reduction in hemoglobin concentration below normal levels, with severity classification guiding treatment approach, including mild (Hb ≥10 g/dl to ≤11.9 g/dl), moderate (Hb ≥8.0 g/dl to ≤9.9 g/dl), and severe (Hb <8.0 g/dl) 3
Initial workup for anemia should include complete blood count with indices, iron studies (serum ferritin, transferrin saturation), assessment for inflammation (ESR, CRP), and peripheral blood smear 3, 4, 1

The European Society for Medical Oncology recommends oral iron supplementation with ferrous sulfate 324 mg (65 mg elemental iron) daily or twice daily for iron deficiency anemia, with treatment continued for 3 months after hemoglobin normalization 2, 1
The American Gastroenterological Association suggests that intravenous iron may be preferred over oral iron in inflammatory states, such as active inflammatory bowel disease 4
The National Comprehensive Cancer Network recommends erythropoiesis-stimulating agents (ESAs) for chemotherapy-induced anemia with Hb ≤10 g/dl, but not for mild to moderate anemia with heart disease 5, 1

The World Health Organization recommends starting oral, low-dose (30 mg/day) iron supplements at the first prenatal visit for pregnant women, with 60-120 mg/day prescribed for anemia during pregnancy 7
The Crohn's and Colitis Foundation of America suggests that ferritin levels <30 μg/L indicate absolute iron deficiency in inflammatory bowel disease, with intravenous iron preferred in active inflammation 4

The American College of Physicians recommends repeating hemoglobin measurement after 4 weeks of treatment, with monitoring for recurrence of anemia, especially in inflammatory conditions (>50% recur within 1 year) 3, 4

The European Society for Medical Oncology notes that failure to identify and treat the underlying cause can lead to recurrence, with ferritin an acute phase reactant that may be falsely elevated in inflammatory states 1, 4
The American Society of Clinical Oncology warns that ESAs carry risks including hypertension, thromboembolism, and potential tumor progression in cancer patients, with transfusions associated with risks including iron overload and infection transmission 1